<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003669</url>
  </required_header>
  <id_info>
    <org_study_id>2141</org_study_id>
    <secondary_id>LILLY-H4Z-MC-JWWI</secondary_id>
    <secondary_id>MSKCC-99001</secondary_id>
    <secondary_id>CDR0000066766</secondary_id>
    <nct_id>NCT00003669</nct_id>
  </id_info>
  <brief_title>Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer</brief_title>
  <official_title>Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy&#xD;
      using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of&#xD;
      estrogen by the tumor cells&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating&#xD;
      women with recurrent, advanced, or metastatic endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the objective tumor response rate (complete response and partial&#xD;
      response) to arzoxifene hydrochloride in patients with recurrent or advanced endometrial&#xD;
      cancer. II. Determine the time to progressive disease, time to treatment failure, response&#xD;
      duration, and survival in patients with recurrent or advanced endometrial cancer receiving&#xD;
      arzoxifene hydrochloride. III. Assess the safety of this treatment in these patients. IV.&#xD;
      Measure changes in serum estradiol, follicle stimulating hormone, luteinizing hormone, and&#xD;
      sex hormone binding globulin during this treatment in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral arzoxifene hydrochloride daily at a fixed dose. Treatment&#xD;
      continues in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified&#xD;
&#xD;
      National Cancer Institute (NCI) registered this trial with Eli Lilly as sponsor. NCI did not&#xD;
      update the record when the trial completed. In June 2012, NCI transferred the trial to&#xD;
      Lilly's clinicaltrials.gov account and Lilly updated the record with the trial completion&#xD;
      date. This trial is not an applicable trial under Food and Drug Administration Amendments Act&#xD;
      of 2007 (FDAAA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">April 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arzoxifene hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed recurrent, advanced, or metastatic&#xD;
        endometrial cancer not amenable to curative surgery or radiotherapy Patients should have&#xD;
        previously undergone radical surgery (minimum of total abdominal hysterectomy and&#xD;
        bisalpingoophorectomy), radical radiotherapy, or not be candidate for such procedures&#xD;
        Bidimensionally measurable disease by x-ray, CT scan, MRI, or physical exam No papillary&#xD;
        serous or clear cell carcinomas of the endometrium Hormone receptor status: Estrogen&#xD;
        receptor positive and/or progesterone receptor positive Unknown receptor status patients&#xD;
        allowed provided (1) original tumor was well- or moderately-well differentiated (2) had&#xD;
        endometrioid histology&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Menopausal&#xD;
        status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count&#xD;
        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL&#xD;
        (transfusion-independent) Prothrombin time or activated partial thromboplastin time no&#xD;
        greater than 1.25 times upper limit of normal (ULN) Hepatic: Bilirubin no greater than 1.5&#xD;
        times normal ALT or AST no greater than 2.5 times ULN (ALT and AST no greater than 5 times&#xD;
        ULN in the presence of liver metastases) Renal: Creatinine no greater than 1.5 ULN Other:&#xD;
        No other primary malignancy within the past 5 years except adequately treated&#xD;
        nonmelanomatous cancer of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        chemotherapy for recurrent or metastatic endometrial cancer At least 1 year since prior&#xD;
        adjuvant chemotherapy Endocrine therapy: No prior antiestrogen therapy for any stage of&#xD;
        endometrial cancer At least 12 months from time of diagnosis since prior raloxifene Prior&#xD;
        progesterone treatment allowed Radiotherapy: See Disease Characteristics At least 2 weeks&#xD;
        since prior radiotherapy and recovered Surgery: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntington Memorial Hospital</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91109-7013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant/Riverside Methodist Hospitals</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S. Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

